Drugs / POLAT-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05935527 | Apr 2023 → Sep 2024 | eyelid disorder | Peregrine Ophthalmic | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | POLAT-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05935527 ↗ |
| Route | Other | “POLAT-001 will be injected into the eyebags at three of the visits.” NCT05935527 ↗ |